HOME      RESEARCH      PEOPLE      THE LAB      PUBLICATIONS      GALLERY      CONTACTS      LINKS


Publications


Original research articles

40)
Zolk O, Hafner S, Schmidt CQ.
COVID-19 pandemic and therapy with ibuprofen or renin-angiotensin system blockers: no need for interruptions or changes in ongoing chronic treatments.
Naunyn Schmiedebergs Arch Pharmacol. 2020. [online ahead of print].

39)

Harder MJ, Höchsmann B, Dopler A, Anliker M, Weinstock C, Skerra A, Simmet T, Schrezenmeier H,
Schmidt CQ
.
Different Levels of Incomplete Terminal Pathway Inhibition by Eculizumab and the Clinical Response of PNH Patients.
Front Immunol. 2019. 10:1639.


38)
Lang SJ, Schmiech M, Hafner S, Paetz C, Steinborn C, Huber R, Gaafary ME, Werner K, Schmidt CQ, Syrovets T, Simmet T.
Antitumor activity of an Artemisia annua herbal preparation and identification of active ingredients.
Phytomedicine. 2019. 62:152962


37)
Pouw RB, Brouwer MC, de Gast M, van Beek AE, van den Heuvel LP, Schmidt CQ, van der Ende A, Sanchez-Corral P, Kuilpers TW, Wouters D.
Potentiation of complement regulator Factor H protects human endothelial cells from complement attack in aHUS sera.
Blood Adv. 2019. 3(4):621-632

36)
Dopler A, Guntau L, Harder MJ, Palmer A, Höchsmann B, Schrezenmeier H, Simmet T, Huber-Lang M,
Schmidt CQ

Self versus Nonself Discrimination by the Soluble Complement Regulators Factor H and FHL-1.
J Immunol. 2019. 202(7):2082-294

35)
Anliker M, Schmidt CQ, Harder MJ, Ganchev G, Zabern I, Höchsmann B, Schrezenmeier H, Weinstock C Complement activation by human anti-red cell antibodies: hemolytic potential of antibodies and efficacy of complement inhibitors assessed by a sensitive flow cytometric assay.
Transfusion. 2018. 58(12):2992-3002

34)
Schmidt CQ*, Ederveen ALH, Harder MJ, Wuhrer M, Stehle T, Blaum BS*.
Biophysical analysis of sialic acid recognition by the complement regulator Factor H.
Glycobiology. 2018. 28(10):765-773  
                                                                              * corresponding authors

33)
Gruszczyk J, Kanjee U, Chan LJ, Menant S, Malleret B, Lim NTY, Schmidt CQ, Mok YF, Lin KM, Pearson RD, Rangel G, Smith BJ, Call MJ, Weekes MP, Griffin MDW, Murphy JM, Abraham J, Sriprawat K, Menezes MJ, Ferreira MU, Russell B, Renia L, Duraisingh MT, Tham WH
Transferrin receptor 1 is a reticulocyte-specific receptor for Plasmodium vivax.
Science. 2018. 359(6371): 48-55

32)

Schmidt C, Loos C, Jin L, Schmiech M, Schmidt CQ, Gaafary ME, Syrovets T, Simmet T.
Acetyl-lupeolic acid inhibits Akt signaling and induces apoptosis in chemoresistant prostate cancer cells in vitro and in vivo.
Oncotarget. 2017. 8(33):55147-55161.
 
31)
Xue X, Wu J, Ricklin D, Forneris F, Di Crescenzio P, Schmidt CQ, Granneman J, Sharp TH, Lambris JD, Gros P.
Regulator-dependent mechanisms of C3b processing by factor I allow differentiation of immune responses.
Nat Struct Mol Biol. 2017. 24(8):643-651.

30)
Harder MJ, Kuhn N, Schrezenmeier H, Höchsmann B, von Zabern I, Weinstock C, Simmet T, Ricklin D, Lambris JD, Skerra A,
*Anliker M, *Schmidt CQ.
Incomplete inhibition by eculizumab: mechanistic evidence for residual C5 activity during strong complement activation.
Blood. 2017. 129(8):970-980.
                                                                                           * corresponding authors

29)
Kuhn N, Schmidt CQ, Schlapschy M, Skerra A.
PASylated Coversin, a C5-Specific Complement Inhibitor with Extended Pharmacokinetics, Shows Enhanced Anti-Hemolytic Activity in Vitro.
Bioconjug Chem. 2016. 27(10):2359-2371.

28)
Krutzke L, Prill JM, Engler T, Schmidt CQ, Xu Z, Byrnes AP, Simmet T, Kreppel F.

Substitution of blood coagulation factor X-binding to Ad5 by position-specific PEGylation: Preventing vector clearance and preserving infectivity.
J Control Release. 2016. 235:379-92. 

27)

*Schmidt CQ, Harder MJ, Nichols EM, Hebecker M, Anliker M, Höchsmann B, Simmet T, Csincsi ÁI, Uzonyi B, Pappworth IY, Ricklin D, Lambris JD, Schrezenmeier H, Józsi M, Marchbank KJ.
Selectivity of C3-opsonin targeted complement inhibitors: A distinct advantage in the protection of erythrocytes from paroxysmal nocturnal hemoglobinuria patients.
Immunobiology. 2016. 221(4):503-11                                                                                * corresponding author
                                                                                                                                             
26)
Kennedy AT, Schmidt CQ, Thompson JK, Weiss GE, Taechalertpaisarn T, Gilson PR, Barlow PN, Crabb BS, Cowman AF, Tham WH.

Recruitment of Factor H as a Novel Complement Evasion Strategy for Blood-Stage Plasmodium falciparum Infection.
J Immunol. 2016. 196(3):1239-48

25)
Harder MJ, Anliker M, Höchsmann B, Simmet T, Huber-Lang M, Schrezenmeier H, Ricklin D, Lambris JD, Barlow PN,
*Schmidt CQ.
Comparative Analysis of Novel Complement-Targeted Inhibitors, MiniFH, and the Natural Regulators Factor H and Factor H-like Protein 1 Reveal Functional Determinants of Complement Regulation.
J Immunol. 2016. 196(2):866-76.                                                                                       * corresponding author 
                                                                                                                                             
24)

Lim NT, Harder MJ, Kennedy AT, Lin CS, Weir C, Cowman AF, Call MJ, Schmidt CQ, Tham WH. Characterization of inhibitors and monoclonal antibodies that modulate the interaction between Plasmodium falciparum adhesin PfRh4 with its erythrocyte receptor complement receptor 1.
J Biol Chem. 2015. 290(42):25307-21.


23)
Lin Z, Schmidt CQ, Koutsogiannaki S, Ricci P, Risitano AM, Lambris JD, Ricklin D. Complement C3dg-mediated erythrophagocytosis: implications for paroxysmal nocturnal hemoglobinuria.
Blood. 2015. 126(7):891-4.

22)
Lucas T, Benihoud K, Vigant F, Schmidt CQ, Bachem MG, Simmet T, Kochanek S. Hexon Modification to Improve the Activity of Oncolytic Adenovirus Vectors against Neoplastic and Stromal Cells in Pancreatic Cancer.
PLoS One. 2015. 10(2):e0117254.

21)
El Gafaary M, Buchele B, Syrovets T, Agnolet S, Schneider B, Schmidt CQ, Simmet T. An α-Acetoxy-Tirucallic Acid Isomer Inhibits Akt/mTOR Signaling and Induces Oxidative Stress in Prostate Cancer Cells.
J Pharmacol Exp Ther. 2015. 352(1):33-42.

20)
Clark SJ, Schmidt CQ, White AM, Hakobyan S, Morgan BP, Bishop PN. Identification of Factor H-like Protein 1 as the Predominant Complement Regulator in Bruch's Membrane: Implications for Age-Related Macular Degeneration.
J Immunol. 2014. 193(10):4962-70.

19)
Park HJ, Guariento M, Maciejewski M, Hauhart R, Tham WH, Cowman AF, Schmidt CQ, Mertens HD, Liszewski MK, Hourcade DE, Barlow PN, Atkinson JP. Using mutagenesis and structural biology to map the binding site for the Plasmodium falciparum merozoite protein PfRh4 on the human immune adherence receptor.
J Biol Chem. 2014. 289(1):450-63.

18)
Krauss J, Gratzl C, Sturm V, Müller C, Staudacher V, Schmidt CQ, Bracher F. Synthesis and Biological Evaluation of Novel Alkyl-Imidazolyl Carbinols and their Esters: Potent Antimycotics.
Sci Pharm. 2013. 81(3):641-50.

17)
Schmidt CQ, Bai H, Lin Z, Risitano AM, Barlow PN, Ricklin D, Lambris JD. Rational engineering of a minimized immune inhibitor with unique triple-targeting properties.
J Immunol. 2013. 190(11):5712-21

16)
Makou E, Mertens HD, Maciejewski M, Soares DC, Matis I, Schmidt CQ, Herbert AP, Svergun DI, Barlow PN. Solution Structure of CCP Modules 10-12 Illuminates Functional Architecture of the Complement Regulator, Factor H.
J Mol Biol. 2012. 424(5):295-312

15)
Goodship TH, Pappworth IY, Toth T, Denton M, Houlberg K, McCormick F, Warland D, Moore I, Hunze EM, Staniforth SJ, Hayes C, Cavalcante DP, Kavanagh D, Strain L, Herbert AP, Schmidt CQ, Barlow PN, Harris CL, Marchbank KJ. Factor H autoantibodies in membranoproliferative glomerulonephritis.
Mol Immunol. 2012. 52(3-4):200-206.

14)
Tetteh-Quarcoo PB, Schmidt CQ, Tham WH, Hauhart R, Mertens HD, Rowe A, Atkinson JP, Cowman AF, Rowe JA, Barlow PN. Lack of evidence from studies of soluble protein fragments that Knops blood group polymorphisms in complement receptor-type 1 are driven by malaria.
PLoS One
. 2012. 7(4):e34820. 


13)
Morgan HP, Mertens HD, Guariento M, Schmidt CQ, Soares DC, Svergun DI, Herbert AP, Barlow PN, Hannan JP. Structural analysis of the C-terminal region (modules 18-20) of complement regulator factor H (FH).
PLoS One
. 2012. 7(4):e34820. 


12)
*Tham WH, *Schmidt CQ, Hauhart RE, Guariento M, Tetteh-Quarcoo PB, Lopaticki S, Atkinson JP,  Barlow PN, Cowman AF. Plasmodium falciparum uses a key functional site in complement receptor type-1 for invasion of human erythrocytes.
Blood. 2011. 118(7):1923-33                                                                                                     *equal contribution

11)
*Morgan HP, *Schmidt CQ, Guariento M, Blaum BS, Gillespie D, Herbert AP, Kavanagh D, Mertens HD, Svergun DI, Johansson CM, Uhrín D, Barlow PN, Hannan JP. Structural basis for engagement by complement factor H of C3b on a self surface.
Nat Struct Mol Biol. 2011. 8(4):463-70                                                                                   *equal contribution 
                                                                                                                                                 
10)
*Schmidt CQ, Slingsby FC, Richards A, *Barlow PN.  Production of biologically active complement factor H in therapeutically useful quantities.
Protein Expr Purif. 2011. 76(2):254-63                                                                             * corresponding authors
9)
Tham WH, Wilson DW, Lopaticki S, Schmidt CQ, Tetteh-Quarcoo PB, Barlow PN, Richard D, Corbin JE, Beeson JG, Cowman AF. Complement receptor 1 is the host erythrocyte receptor for Plasmodium falciparum PfRh4 invasion ligand.
Proc Natl Acad Sci U S A. 2010. 5;107(40):17327-32.


8)
Dhillon B, Wright AF, Tufail A, Pappworth I, Hayward C, Moore I, Strain L, Kavanagh D, Barlow PN, Herbert AP, Schmidt CQ, Armbrecht AM, Laude A, Deary IJ, Staniforth SJ, Holmes LV, Goodship TH, Marchbank KJ. Complement factor h autoantibodies and age-related macular degeneration. 
Invest Ophthalmol Vis Sci. 2010. 51(11):5858-63.


7)
Leffler J, Herbert AP, Norström E, Schmidt CQ, Barlow PN, Blom AM, Martin M. Annexin-II, DNA, and histones serve as factor H ligands on the surface of apoptotic cells. 
J Biol Chem. 2010. 285(6):3766-76.

6)
Moore I, Strain L, Pappworth I, Kavanagh D, Barlow PN, Herbert AP, Schmidt CQ, Staniforth SJ, Holmes LV, Ward R, Morgan L, Goodship TH, Marchbank KJ.  Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome. 
Blood. 2010. 115(2):379-87.

5)
Schmidt CQ, Herbert AP, Mertens HD, Guariento M, Soares DC, Uhrin D, Rowe AJ, Svergun DI, Barlow PN. The central portion of factor H (modules 10-15) is compact and contains a structurally deviant CCP module.  
J Mol Biol. 2010. 395(1):105-22.

4)
Faull PA, Florance H, Schmidt CQ, Tomczykc N, Barlow PN, Hupp TR, Nikolovad PV, Barran PE. Utilising ion-mobility mass spectrometry to interrogate macromolecules: Factor H complement control protein modules 10-15 and 19-20 and the DNA-binding core domain of tumour suppressor p53. 
J Mass Spectrom. 2010. 298(1-3):99-110

3)
Schmidt CQ, Herbert AP, Kavanagh D, Gandy C, Fenton CJ, Blaum BS, Lyon M, Uhrín D, Barlow PN. A new map of glycosaminoglycan and C3b binding sites on factor H. 
J Immunol. 2008. 181(4):2610-9

2)
Schmidt CQ, Messmer R, Bracher F, Krauss J. A New Approach to Furan-Containing Macrolactones. 
Turk J Chem., 2007. 31:251-256

1)
Herbert AP, Deakin JA, Schmidt CQ, Blaum BS, Egan C, Ferreira VP, Pangburn MK, Lyon M, Uhrín D, Barlow PN. Structure shows that a glycosaminoglycan and protein recognition site in factor H is perturbed by age-related macular degeneration-linked single nucleotide polymorphism.
J Biol Chem. 2007. 282(26):18960-8.




Reviews & editorial articles


7)
Dopler A, Guntau L, Harder MJ, Palmer A, Höchsmann B, Schrezenmeier H, Simmet T, Huber-Lang M,
*Schmidt CQ
.
Response to Comment on "Self versus Nonself Discrimination by the Soluble Complement Regulators Factor H and FHL-1".

J Immunol. 2019. 203(8):2029-2030                                                                                   * corresponding author

6)
Halbgebauer R, Schmidt CQ, Karsten CM, Ignatius A, Huber-Lang M.
Janus face of complement-driven neutrophil activation during sepsis.
Semin Immunol. 2018. pii: S1044-5323(17)30117-3.

5)
Schmidt CQ and Verschoor A.
Complement and coagulation: so close, yet so far. 

Blood. 2017. 130(24):2581-2582.

4)

*Schmidt CQ, Lambris JD, Ricklin D.
Protection of host cells by complement regulators.
Immunol Rev. 2016. 274(1):152-171.
                                                                                * corresponding author
                                                                                                                                             
3)
Huber-Lang M, Gebhard F, Schmidt CQ, Palmer A, Denk S, Wiegner R.
Complement therapeutic strategies in trauma, hemorrhagic shock and systemic inflammation - closing Pandora's box?
Semin Immunol. 2016. 28(3):278-84.
       
2)

*Schmidt CQ, Kennedy AT, *Tham WH.
More than just immune evasion: Hijacking complement by Plasmodium falciparum.

Mol Immunol. 2015. 67(1):71-84.                                                                                     * corresponding authors
                                                                                                                                            
1)
Schmidt CQ, Herbert AP, Hocking HG, Uhrín D, Barlow PN.
Translational mini-review series on complement factor H: structural and functional correlations for factor H. 

Clin Exp Immunol. 2008. 151(1):14-24.



Patent Applications


4) COMPLEMENT INHIBITORS AND USES THEREOF
Inventors: Schmidt, Christoph; Huber-Lang, Markus
European Patent Application No.: EP18179269.8 (Jahr: 2018)

3)
COMPLEMENT INHIBITORS AND USES THEREOF

Inventors: Schmidt, Christoph; Schrezenmeier, Hubert, Anliker, Markus, Höchsmann, Britta
International Application No.: PCT/EP2017/065979 

2)

REGULATOR OF COMPLEMENT ACTIVATION AND USES THEREOF
Inventors: Lambris, John, D.; Schmidt, Christoph; Ricklin, Daniel;
International Application No.: PCT/US2013/032350


1)
RECOMBINANT FACTOR H AND VARIANTS AND CONJUGATES THEREOF
Inventors: Schmidt, Christoph; Barlow, Paul, N.; Richards, Anna;
International Application No.: PCT/GB2010/002334



Granted Patents 

2)
REGULATOR OF COMPLEMENT ACTIVATION AND USES THEREOF
Inventors: Lambris, John, D.; Schmidt, Christoph; Ricklin, Daniel;
International Application No.: 
PCT/US2013/032350 (see above)
publication number: US9540626 B2  
publication date: 10.Jan.2017 

1)

RECOMBINANT CODON OPTIMISED FACTOR H
Inventors: Schmidt, Christoph; Barlow, Paul, N.; Richards, Anna;
International Application No.: PCT/GB2010/002334 (see above)
publication number: US 8889374 B2
publication date: 18.Nov.2014 




Protein data bank entries (www.pdb.org)

2JGX, 2JGW, 2KMS, 3OXU, 3SW0, 4B2R, 4B2S, 2MCZ, 2MCY


© 2020 Christoph Schmidt, all rights reserved